BIOLASE Balance Sheet Health
Financial Health criteria checks 2/6
BIOLASE has a total shareholder equity of $2.0M and total debt of $14.0M, which brings its debt-to-equity ratio to 718.1%. Its total assets and total liabilities are $35.1M and $33.1M respectively.
Key information
718.1%
Debt to equity ratio
US$14.05m
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.57m |
| Equity | US$1.96m |
| Total liabilities | US$33.15m |
| Total assets | US$35.10m |
Recent financial health updates
Recent updates
Biolase partners with dental speciality programs across U.S.
Aug 31BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity
Jul 21BIOLASE amends senior secured term loan with SWK Funding
Jul 01BIOLASE: Bad News Across The Board - Sell
Mar 21Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?
Feb 24
BIOLASE - Speculative Buy After Strong Preliminary Q4 Results
Jan 11BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors
Nov 24Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?
Jul 14Biolase shares jump 11% after regaining Nasdaq compliance
Feb 04Biolase: Business Recovery On The Way But Warrant Overhang Should Keep Investors Sidelined
Feb 01BIOLASE's (NASDAQ:BIOL) Stock Price Has Reduced 78% In The Past Five Years
Jan 24
BIOLASE strikes deal with Dental Care Alliance in laser adoption push
Jan 12Health Check: How Prudently Does BIOLASE (NASDAQ:BIOL) Use Debt?
Dec 02Financial Position Analysis
Short Term Liabilities: BIOL's short term assets ($24.9M) exceed its short term liabilities ($19.7M).
Long Term Liabilities: BIOL's short term assets ($24.9M) exceed its long term liabilities ($13.5M).
Debt to Equity History and Analysis
Debt Level: BIOL's net debt to equity ratio (382.5%) is considered high.
Reducing Debt: BIOL's debt to equity ratio has increased from 97.7% to 718.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIOL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BIOL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.8% each year